
PODD
Insulet Corporation
Company Overview
| Mkt Cap | $20.84B | Price | $251.11 |
| Volume | 543.96K | Change | -2.15% |
| P/E Ratio | 49.8 | Open | $255.83 |
| Revenue | $2.1B | Prev Close | $256.62 |
| Net Income | $418.3M | 52W Range | $230.05 - $354.88 |
| Div Yield | N/A | Target | $372.79 |
| Overall | 43 | Value | 30 |
| Quality | 68 | Technical | 33 |
No chart data available
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News
Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD)
Insulet (PODD) Receives a Buy from Bernstein
Wells Fargo Sticks to Their Buy Rating for Insulet (PODD)
RBC Capital Sticks to Their Buy Rating for Insulet (PODD)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PODD | $251.11 | -2.1% | 543.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |